Company transfers equity stake in a strategic deal for future capital rights, resolving outstanding brand disputes and boosting investor confidence.
The biotech company's shares surged after announcing an ambitious plan for its sublingual drug delivery technology and boosting its 2026 financial outlook.
The non-dilutive capital is aimed at advancing the company's battery manufacturing capabilities and bolstering its position in the U.S. supply chain.
The approval covers a first-line maintenance treatment for an aggressive form of small cell lung cancer, a historically difficult-to-treat disease.
The ongoing government shutdown has postponed the release of key economic data, leaving the Federal Reserve and investors in the dark.
The regulator's green light for Rhapsido, a first-in-class oral treatment for chronic hives, positions the company to challenge injectable rivals.
Autonomous trucking firm's shares rose 2.2% in after-hours trading after the billionaire's fund disclosed a 5.7% passive investment.
Gene therapy candidate TSHA-102 for Rett syndrome receives key designation, paving the way for an accelerated regulatory pathway.